In light of the recently published LAP07 trial, what is the role of radiation in unresectable pancreatic cancer?  

In LAP07's second randomization (capecitabine+54 Gy vs maintenance gemcitabine +/- erlotinib), 60% of unresectable pancreatic cancer patients who did not progress after 4 months of induction gemcitabine +/- erlotinib, RT increased local control from 54% to 68% without significantly improving PFS or OS. Is there reason to believe hypofractionated RT or SBRT will achieve local control better than 68%, and that the improvement will prolong survival?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Lake Huron Medical Center
@Christopher H. Crane - how do you simulate t...
Radiation Oncologist at Memorial Sloan-Kettering Cancer Center
We have published these details in multiple places...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice